Regeneron and Sanofi’s Praluent gets European approval for reducing cardiovascular risk in atherosclerotic disease patients

pharmanewsdaily- March 24, 2019 0

Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission's (EC) approval of Praluent (alirocumab) for a new indication. The approval enables ... Read More

Ablynx secures FDA approval for Cablivi to treat aTTP

pharmanewsdaily- February 10, 2019 0

In a significant milestone for Belgian biopharma company Ablynx, the U.S. Food and Drug Administration (FDA) has granted approval for Cablivi (caplacizumab-yhdp), a nanobody designed ... Read More

Dupixent receives FDA approval for treatment of moderate-to-severe asthma

pharmanewsdaily- October 21, 2018 0

Sanofi and Regeneron Pharmaceuticals' Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving it as an add-on maintenance ... Read More

Sanofi to build new $396m vaccine manufacturing facility in Toronto

pallavi123- April 15, 2018 0

Significant Investment in Vaccine Production: French pharmaceutical giant Sanofi has announced plans to invest CAD 500 million (approximately $396.3 million) to construct a new vaccine ... Read More

Sanofi to acquire Belgian biotech firm Ablynx for €3.9bn in all-cash deal

pallavi123- January 30, 2018 0

French pharmaceutical giant Sanofi has successfully finalized an agreement to acquire Ablynx, a Belgian biotechnology firm, for approximately €3.9 billion. This strategic acquisition surpasses a ... Read More

Sanofi to acquire Bioverativ for $11.6bn to expand into rare blood disorders

pallavi123- January 22, 2018 0

Sanofi has announced a definitive agreement to acquire Bioverativ, a US biotechnology company specializing in the treatment of hemophilia and other rare blood disorders, for ... Read More

Sanofi strikes $805m deal with Principia Biopharma for multiple sclerosis drug development

pallavi123- November 12, 2017 0

Sanofi and Principia Biopharma have announced a significant partnership to develop and commercialize PRN2246, a promising oral drug candidate for multiple sclerosis (MS) and other ... Read More

Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment

pharmanewsdaily- April 2, 2017 0

Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the ... Read More

AstraZeneca and Sanofi Pasteur forge €615m alliance to develop infant respiratory drug MEDI8897

pharmanewsdaily- March 6, 2017 0

AstraZeneca’s biotech arm, MedImmune, and Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, have entered into a significant research and development collaboration. The ... Read More

Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial

pharmanewsdaily- March 5, 2017 0

Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase ... Read More